Conceptus
This article was originally published in The Gray Sheet
Executive Summary
Developer of the STOP (selective tubal occlusion procedure) non-surgical permanent contraception device for women announces completion of a private placement of 1.9 mil. shares at $7.26 each. Net proceeds of $14 mil. will allow Conceptus to "continue to ramp up our pivotal trial of the STOP device, accelerate marketing in Australia and other international markets, and...invest in our manufacturing and distribution operations," the company says. PaineWebber served as placement agent